Abstract:OBJECTIVE:To amplify and express the gene encoding murine single-chain fragment variable (scFv) antibody against human cervical cancer and predict the secondary structure and three-dimensional structure of the antibody. METHODS:The gene fragments coding for the variable region of the heavy and light chains of scFv antibody against human cervical cancer were amplified respectively using recombinant DNA techniques from CsA125 hybridoma cells, and spliced together using a flexible linker to the antibody. The scFv genes were then cloned into the expression vector pCANTAB 5E and expressed in E.coli HB2151 and TG1, respectively. The scFv antibody obtained was assayed using SDS-PAGE, Western blotting, and immunohistochemical analysis, with its secondary structure and three-dimensional structure predicted with Swiss-model and 3dpssm. The physicochemical properties of the antibody were analyzed with Antheprot software. RESULTS:The expressed scFv antibody was soluble and phage-displayed. The specific binding capacity of the soluble and phage-displayed scFv antibody to the surface-associated antigen of human cervical cancer cell line were further confirmed. The scFv antibody had a relative molecular mass of 32,000 as was consistent to theoretical prediction, with pI of 7.215 and characterized to belong to alpha+beta protein. The antibody contained many protein kinase C phosphorylation sites and casein kinase II phosphorylation sites in both the VH and VL domains. Computer graphic modeling indicated that the linker was isolated from the VH and VL domains, which formed a hydrophobic pocket in the molecule to facilitate antigen binding. CONCLUSIONS:The soluble and phage displayed scFv antibody expressed in E. coli against human cervical cancer shows high and specific affinity to the cervical cancer cell line surface-associated antigen. The construction and analysis of the molecular model of the antibody may facilitate further studies in engineering of the antibody and exploration of the mechanism of the antigen-antibody interaction.

Prediction of B cell epitopes and HLA restricted CTL epitopes of human cervical cancer oncogene protein

Identification of predicted epitopes of HLA-A * 0201-restricted cytotoxic T lymphocytes derived from human papillomavirus type 11 E7 antigen

Mapping of Cytotoxic T Lymphocytes Epitopes in E7 Antigen of Human Papillomavirus Type 11

Prediction and identification of HLA-A0201 restricted CTL epitopes derived from human telomerase reverse transcriptase antigen

Prediction, Synthesis and Identification of HLA-A2-restricted Cytotoxic T Lymphocyte Epitopes of the Tumor Antigen MAGE-n

Prediction and analysis of secondary structures and immune epitopes for Helicobacter pylori VacA,CagA and BabA proteins

Prediction and Identification of HLA-A * 0201-Restricted CTL Epitopes from Htert

Recombinant protein expression and monoclonal antibody preparation of HCCR

Identification of new cytotoxic T-lymphocyte epitopes from cancer testis antigen HCA587.

Prediction and Peptide Binding Analysis of HLA-A*0201-restricted CTL Epitope from MUC4

Whole-exome Sequencing Predicted Cancer Epitope Trees of 23 Early Cervical Cancers in Chinese Women

Prediction of B-cell epitopes on human ovarian cancer-associated antigen OVA66

Identification of promiscuous HLA-DR-restricted CD4⁺ T-cell epitopes on the cancer-testis antigen HCA587.

A Modified HLA-A*0201-restricted CTL Epitope from Human Oncoprotein (hpebp4) Induces More Efficient Antitumor Responses

[Expression, structure prediction and functional analysis of murine single-chain fragment variable antibody against human cervical cancer].

Immunoinformatics Design and In Vivo Immunogenicity Evaluation of a Conserved CTL Multi-Epitope Vaccine Targeting HPV16 E5, E6, and E7 Proteins

Prediction and Identification of HLA-A2 Restricted CTL Epitope Derived from the Leukemia-Associated Antigen MLAA-34

Predictive Value and Immunological Role of the HSPA5 Gene in Cervical Cancer

Identification of HLA-A2 restricted epitopes of glypican-3 and induction of CTL responses in HLA-A2 transgenic mice

Computational Identification, Characterization and Validation of Potential Antigenic Peptide Vaccines from Hrhpvs E6 Proteins Using Immunoinformatics and Computational Systems Biology Approaches.

Identification of Promiscuous HLA‐DR‐restricted CD4+ T‐cell Epitopes on the Cancer‐testis Antigen HCA587